Geron Corporation Announces Conference Call To Discuss Fourth Quarter And Annual 2014 Financial Results And Recent Events
Menlo Park, Calif., February 26, 2015 - Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2014, on Tuesday, March 3, 2015, after the market close. Geron's management will also host a conference call for analysts and investors on Tuesday, March 3, 2015, at 4:30 p.m. Eastern Time to discuss the company's fourth quarter and annual results and recent events.
Participants can access the conference call live via telephone by dialing (877) 703-6107 (U.S.); (857) 244-7306 (international). The passcode is 28650149. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://edge.media-server.com/m/p/bu63s9fe/lan/en. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through April 3, 2015.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Kevin Eng, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com
Help employers find you! Check out all the jobs and post your resume.
Participants can access the conference call live via telephone by dialing (877) 703-6107 (U.S.); (857) 244-7306 (international). The passcode is 28650149. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://edge.media-server.com/m/p/bu63s9fe/lan/en. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through April 3, 2015.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Kevin Eng, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com
Help employers find you! Check out all the jobs and post your resume.